Economic evaluation for the United Kingdom (UK) of systemic chemotherapies as first-line treatment for metastatic pancreatic cancer (MPC)
- At: 2016 FIP Congress in Buenos Aires (Argentina)
- Type: Poster
- By: ABRAHAM, Ivo (UNIVERSITY OF ARIZONA, Pharmacy Practice and Science, Tucson, United States)
- Co-author(s): Mahdi Gharaibeh:Center for Health Outcomes and PharmacoEconomic Research,UNIVERSITY OF ARIZONA,Tucson,United States|Ivo Abraham:Center for Health Outcomes and PharmacoEconomic Research,UNIVERSITY OF ARIZONA,Tucson,United States;Arizona Cancer Center,UNIVERSITY OF ARIZONA,Tucson,United States
NAB-P+GEM and FFX have shown superior survival efficacy over GEM alone as first-line treatment for MPC. Meta-analysis showed Statistical significant improvement in OS detected especially with CIS+GEM, CAP+GEM, or OX+GEM.
We used published direct and indirect efficacy estimates of FOLFIRINOX v. other regimens from published network meta-analysis. A.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.